Gas chromatography/mass spectrometry (GC/MS) remains a pre-eminent discovery tool in clinical steroid investigations even in the era of fast liquid chromatography tandem mass spectrometry (LC/MS/MS).
Krone N, Hughes BA, Lavery GG, Stewart PM, Arlt W, Shackleton CH. · 2010
Read Gas chromatography/mass spectrometry (GC/MS) remains a pre-eminent discovery tool in clinical steroid investigations even in the era of fast liquid chromatography tandem mass spectrometry (LC/MS/MS). by Krone N, Hughes BA, Lavery GG, Stewart PM, Arlt W, Shackleton CH. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2941839.txt.
Introduction
Krone and co-authors argued in 2010 that an older lab method, gas chromatography with mass spectrometry, still leads in discovering steroid disorders. A newer liquid-based method was taking over routine hormone testing thanks to small samples and sharper targeting.
The newer approach excels at measuring single known steroids but misses the wider picture. A gas-based scan captures every steroid in a urine sample at once, revealing whole patterns of hormone output. Nearly all inherited steroid faults, from early discoveries to recent ones involving oxidoreductase faults, were first defined this way. Presenting the flood of data remains the method's weak point.
Catalog record
| CREATOR | Krone N, Hughes BA, Lavery GG, Stewart PM, Arlt W, Shackleton CH. |
|---|---|
| YEAR | 2010 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Gas chromatography/mass spectrometry (GC/MS) remains a pre-eminent discovery tool in clinical steroid investigations even in the era of fast liquid chromatography tandem mass spectrometry (LC/MS/MS)☆ By Nils Krone, Beverly A Hughes, Gareth G Lavery, Paul M Stewart, Wiebke Arlt, Cedric HL Shackleton Published in: The Journal of Steroid Biochemistry and Molecular Biology DOI: 10.1016/j.jsbmb.2010.04.010 ABSTRACT Abstract Liquid chromatography tandem mass spectrometry (LC/MS/MS) is replacing classical methods for steroid hormone analysis. It requires small sample volumes and has given rise to improved specificity and short analysis times. Its growth has been fueled by criticism of the validity of steroid analysis by older techniques, testosterone measurements being a prime example. While this approach is the gold-standard for measurement of individual steroids, and panels of such compounds, LC/MS/MS is of limited use in defining novel metabolomes. GC/MS, in contrast, is unsuited to rapid high-sensitivity analysis of specific compounds, but remains the most powerful discovery tool for defining steroid disorder metabolomes. Since the 1930s almost all inborn errors in steroidogenesis have been first defined through their urinary steroid excretion. In the last 30 years, this has been exclusively carried out by GC/MS and has defined conditions such as AME syndrome, glucocorticoid remediable aldosteronism (GRA) and Smith–Lemli–Opitz syndrome. Our recent foci have been on P450 oxidoreductase deficiency (ORD) and apparent cortisone reductase deficiency (ACRD). In contrast to LC/MS/MS methodology, a particular benefit of GC/MS is its non-selective nature; a scanned run will contain every steroid excreted, providing an integrated picture of an individual's metabolome. The “Achilles heel” of clinical GC/MS profiling may be data presentation. There is lack of familiarity with the multiple hormone metabolites excreted and diagnostic data are difficult for endocrinologists to comprehend. While several conditions are defined by the absolute concentration of steroid metabolites, many are readily diagnosed by ratios between steroid metabolites (precursor metabolite/product metabolite). Our work has led us to develop a simplified graphical representation of quantitative urinary steroid hormone profiles and diagnostic ratios. Keywords: Gas chromatography/mass spectrometry, GC/MS, Tandem mass spectrometry, P450 oxidoreductase deficiency, ORD, Apparent cortisone reductase deficiency, ACRD INTRODUCTION Urinary steroid profiling has been a critical part of the diagnosis of disorders of steroid hormone synthesis and metabolism since the 1960s, first by thin layer chromatography, followed by gas chromatography and gas chromatography–mass spectrometry (GC/MS). However, immunoassays and related techniques have been widely used for quantification of plasma steroid hormones in routine diagnostic processes for established conditions. While such techniques have been central to our ability to diagnose clinical disorders, data are frequently compromised since the problem of cross-reactivity has never been completely solved for several analytes, thus impacting specificity. Another problem commonly occurs when low concentrations of hormones are quantified, as in pediatric patients or postmenopausal women. Furthermore, large interassay variability exists even for common measurements such as testosterone, estradiol, and progesterone [1]. These difference have been significantly lowered between laboratories using liquid chromatography tandem mass spectrometry (LC/MS/MS) [1]. The latest generation of GC/MS and LC/MS/MS techniques are superior to immunoassays regarding specificity and limits of quantification, providing a good linearity even down to low concentrations. Since LC/MS/MS high-sensitivity and high-specificity measurement can be allied with high throughput, many diagnostic laboratories are adopting this new technology. While LC/MS/MS will be the mainstream technology in steroid hormone analysis in the near future, it is not without its limitations, with one drawback being that analyte measurements are always targeted, even when panels of steroids are measured in single runs. The targeted analytes for radioimmunoassays (RIAs) or tandem MS analysis are selected steroid hormones and their precursors illustrated in the steroid biosynthetic pathway (Fig. 1, abbreviations listed in Table 1). Historically the analytes requested for patient studies have been kept to a minimum because of cost and lack of availability of tests for less common analytes. However, with the advent of tandem MS panels steroid hormone profiles will be routinely measured. [Figure: Synthesis and metabolism of hormonal steroids. This figure illustrates the formation of the major hormone classes from cholesterol. Steroid names in conventional script are steroid hormones and precursors; those in italics are urinary metabolites of the aforementioned. The major transformative enzymes are in rectangular boxes, the cofactor (“facilitator”) enzymes in ovals. The pale blue area contains common intermediate steps; the yellow preliminary steps in glucocorticoid synthesis; the green mineralocorticoids; the orange, glucocorticoids; dark blue, androgens and pink, estrogens. Mitochondrial CYP type I enzymes requiring electron transfer via adrenodoxin reductase (ADR) and adrenodoxin (Adx) CYP11A1, CYP11B1, CYP11B2, are marked with a labelled box ADR/Adx. Microsomal CYP type II enzymes receive electrons from P450 oxidoreductase (POR), CYP17A1, CYP21A2, CYP19A1, are marked by circled POR. The 17,20-lyase reaction catalyzed by CYP17A1 requires in addition to POR also cytochrome b5 indicated by a circled b5. Similarly, hexose-6-phosphate dehydrogenase (H6PDH) is the cofactor-generating enzyme for 11β-HSD1. The asterisk (*) indicates the 11-hydroxylation of 17OHP to 21-deoxycortisol in 21-hydroxylase deficiency. The conversion of androstenedione to testosterone is catalyzed by HSD17B3 in the gonad and AKR1C3 (HSD17B5) in the adrenal. StAR, steroidogenic acute regulatory protein; CYP11A1, P450 side-chain cleavage enzyme; HSD3B2, 3β-hydroxysteroid dehydrogenase type 2; CYP17A1, 17α-hydroxylase; CYP21A2, 21-hydroxylase; CYP11B1, 11β-hydroxylase; CYP11B2, aldosterone synthase; HSD17B, 17β-hydroxysteroid dehydrogenase; CYP19A1, P450 aromatase; SRD5A2, 5α-reductase type 2; SULT2A1, sulfotransferase 2A1; PAPPS2, 3′-phosphoadenosine 5′-phosphosulfate synthase 2.] [Table: Abbreviations of steroid hormone metabolites.] An alternative analytical technique available for 40 years is gas chromatography mass spectrometry (GC/MS). GC/MS is used to analyse the metabolites of steroid hormones and their precursors (steroid metabolite abbreviations in italic script in Fig. 1). This technique can readily be utilized in comprehensive (full scan) and targeted (selected ion) mode. A “scanned” GC/MS run contains all steroids excreted and the data set can be searched for any required analyte even years after the analysis. For the last 70 years almost all disorders of steroid hormone biosynthesis and metabolism have been characterized and first named following urine steroid analysis. The most recently described examples have had their steroid phenotype established using GC/MS, emphasizing the diagnostic power and discovery potential of this technique. Many believe tandem MS sounds the death knell of GC/MS. In contrast, while we believe that LC/MS/MS of serum steroid hormones will dominate clinical analysis, GC/MS of excreted metabolites will retain an important role. The techniques will be complementary rather than competitive. LC/MS/MS will be the method of choice to determine targeted steroids and profiles of such, whereas GC/MS will probably remain the pre-eminent tool for novel steroid metabolome discovery. GC/MS has also an additional role as a non-invasive and integrative method for known disorders of steroidogenesis, particularly useful in young infants. One of the biggest drawbacks to the adoption of GC/MS methodology in clinical steroidology has been the presentation of data in a simple form, interpretable by endocrinologists unfamiliar with the intricacies of steroid metabolism. We present an improved visual presentation of GC/MS data to make these complex metabolomes user-friendly and easier to understand for clinicians and scientists. To illustrate this, we provide two recent examples of the use of GC/MS to biochemically define novel entities in steroid hormone biology. METHODOLOGY UTILIZED The methods of sample work-up for GC/MS analysis (conjugate hydrolysis, extraction and derivatization) have been published in several papers [2], [3]. While the methodologies have been improved over the years the